Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
What is the risk of local recurrence in a high grade muscle invasive bladder cancer (MIBC) s/p incomplete TURBT treated with concurrent chemoradiation compared to a complete TURBT?
One source I’m aware of that could shed light on this specific question is a 2017 publication from MGH (Giacalone et al., PMID 28081860), reporting the outcomes of 475 patients with T2-4a N0 M0 bladder cancer treated with various protocols from 1986-2013. Not all patients had high-grade tumors, but ...
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
Marginal Zone Lymphoma (MZL) when localized is curable in most instances with modest doses of RT (24-30 Gy), perhaps even less when the primary site is the orbit. It typically responds to rituximab but relapses occur in most cases. Therefore, definitive RT is the treatment of choice in the great maj...
For primary MZL of the breast, do you do whole breast to 24 Gy or ISRT?
Without knowledge of the age of this patient and whether the concern of carcinogenicity from half the normal dose of traditional whole breast radiation (which we obviously do all the time for breast cancer) is enough to warrant omission of curative intent therapy in what is otherwise described as a ...
Would you consider 5-fraction whole breast RT for a patient with multiple positive margins following lumpectomy for whom reexcision is not possible?
It’s not the whole-breast fractionation that matters, as 5 or 15 fractions are adequate doses for whole breast, but I would definitely add a boost equivalent to a dose of 16 Gy to the surgical bed.
How would you approach post-op radiation recommendations in patients who had neoadjuvant chemoimmunotherapy for HPV mediated OPSCC s/p TORS who have a complete pathologic response (pCR)?
Neoadjuvant immunotherapy for patients with TORS-eligible HPV-positive malignancies should not be done off study. KEYNOTE-689 did not include early-stage HPV+ oropharyngeal cancer patients, and as such, there is no prospective data to suggest a benefit to neoadjuvant immunotherapy in this patient po...
What dose constraints do you use for 15-25 fraction hypofractionated RT for cholangiocarcinoma?
5Fx 10fx 15fx 25fx Ablative dose 50Gy 60Gy 67.5Gy 75Gy GI tract pt dose (0.2cc) 30Gy 40Gy 45Gy 60Gy Bile Duct pt dose (0.2cc) 40Gy 65Gy 70Gy 80Gy Liver – GTV Mean dose + 700cc below + 1/3 liver over 15Gy 20Gy 24Gy 28Gy Mean dose CP...
How do you manage neurocognitive decline associated with chemotherapy (i.e. chemo brain)?
I agree with @Dr. First Last's detailed response. Practically speaking, I would also add that it is important to listen and validate your patient's concerns and respond to their frustration and sense of loss. A diagnostic evaluation will not only help you and your patient discover or 'rule out' othe...
When using FAST Forward, how important is it for the treatment to be delivered Monday through Friday in one week as opposed to spanning a weekend?
Presumably unimportant. From the protocol: "13. TREATMENT SCHEDULING AND GAPSTreatment can start on any day of the week.A gap of up to 3 days is acceptable in the event of machine service or breakdown. This is preferable to transferring the patient to a machine on which daily verification imaging is...
How do you manage an unresectable high-grade glioma of the distal cord/cauda equina?
Doses may vary by institution. Our typically practice is to cover the gross disease to 54 to 50.4 Gy in 1.8’s for conus/cauda and then approximately two vertebral bodies above and below to 50.4-45 Gy (for instance if the superior extent is in true cord, then it’s typically prescribed to 45 Gy with p...
Do you recommend adjustment of lung dose constraints in the setting of stage III lung cancer treated with definitive concurrent chemoradiation followed by planned consolidation immunotherapy?
No, the normal tissue constraints have not changed now that adjuvant durvalumab is the new standard of care. Of course we should always be trying to make our normal tissue dose constraints as low as possible, without underdosing the target. And we should probably assume that all patients are going t...